Shenhong Wu, MD, PhD
Stony Brook University, Hematology and Oncology, USA
Shenhong Wu is an Assistant Professor of Medicine, Stony Brook University Cancer Center, July 2006-present. Efficacy and serious adverse events of new anti-neoplastic treatment, particularly molecularly-targeted agents including sorafenib, sunitinib, and bevacizumab. Investigator-initiated trials under development: 1) Phase 1 study of targeted agents with chemotherapy. 2) Intra-carotid chemotherapy for newly diagnosed glioblastoma multiforme.Medical Oncology Branch, National Cancer Institute-Bethesda, MD.Clinical fellow, July, 2005- June, 2006. Clinical trials of prostate cancer using chemotherapeutic and targeted agents with Dr. William Dahut.University of Chicago - Chicago, IL. Research Associate, 1996 - 2001.Department of Pathology and Committee on Immunology, with Dr. Andrea J. Sant on the antigen processing and presentation to T lymphocytes by MHC class II molecules and DM regulation.Medical College of Wisconsin, Milwaukee, WI.Ph.D. Candidate, 1990 - 1996. Section of Immunogenetics, Blood Research Institute of the Blood Center of Southeastern Wisconsin, with Dr. Jack Gorski on the physiological and pathological antigen presentation by HLA molecules. Department of Pediatrics and Department of Cellular Biology, with Dr. Bahiru Gametchu on the mechanism of glucocorticoid-induced apoptosis mediated by glucocorticoid receptors in human leukemic cells. Shanghai Medical University, Shanghai, China, Resident, 1987-1990.
Targeted therapy, Clinical trials, Genito-urinary cancer and brain tumor, Meta-analysis.
Cancer Science & Therapy received 3358 citations as per Google Scholar report